Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies
Proceeds to Support Advancement of Engrail’s Pipeline for Neuropsychiatric and Neurodevelopmental Disorders March 19, 2024 05:00 AM Pacific Daylight Time SAN DIEGO–(BUSINESS WIRE)–Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the development…